, but for SGLT-2
inhibitors there are additional caveats.
The SGLT-2 inhibitor canagliﬂozin was associated with
an increased risk of amputation in an RCT. This was not
a pre-speciﬁed endpoint and was not observed in the
other SGLT-2 inhibitor trials143 or in long term prospective
studies, as concluded in the ADA-EASD 2022 consensus
report.